Skip to main content
TipRanks
Go Ultimate75% OFF

Chia Tai Enterprises International (3839) AI Stock Analysis

0 Followers
HK:3839

Chia Tai Enterprises International

(HKEX:3839)

Select Model
Rating:61Neutral
Price Target:HKD 8.00â–²(3.90% Upside)
Action:downgraded
Date:08/27/26

The company's improving financial health, marked by a strong balance sheet and positive cash flow turnaround, is the primary support for the score. This is offset by significant headwinds, including a weak technical picture with the stock trading below key moving averages and fundamental concerns over declining gross margins and a sharp deceleration in revenue growth. The low P/E ratio provides some valuation support but is not enough to outweigh the negative momentum.

Positive Factors
Revenue reboundThe sharp 2025 revenue rebound indicates materially stronger business activity and provides a larger base from which the company can improve earnings. If sustained, this growth can support operating leverage, strengthen market participation, and increase the resources available for reinvestment.
Negative Factors
Gross margin compressionThe sustained decline in gross margin suggests that pricing, product mix, or cost pressures have reduced the profitability of each sales dollar. Even with revenue growth, weaker underlying economics could limit operating leverage and make future earnings more sensitive to execution.

Chia Tai Enterprises International (3839) vs. iShares MSCI Hong Kong ETF (EWH)

-20%-10%0%10%20%30%40%50%60%HK:3839+25.61%EWH+9.93%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 270.48M
Dividend Yield
―
Average Volume (3M)
61.90K
Price to Earnings (P/E)
12.0
Beta (1Y)
1.09
Revenue Growth
-22.78%
EPS Growth
-32.03%
Country
Hong Kong
Employees
900
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Chia Tai Enterprises International Business Overview & Revenue Model

Company Description

CPBIO Holding Company Limited produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operations are divided into tw...

How the Company Makes Money

The company makes money primarily by selling and distributing animal health and related agribusiness products and services. Key revenue streams typically include: (1) product sales to farms, distributors, and veterinary channels (e.g., animal health...

Chia Tai Enterprises International Financial Statement Overview

Summary

Solid overall financial health with strong historical revenue growth, a conservative debt-to-equity ratio of 0.17, and a recent turnaround to positive operating and free cash flow. However, the score is tempered by a declining gross margin to 14.4% and a sharp revenue growth slowdown to 2.6% in 2025.

Income Statement

65Positive

Balance Sheet

75Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue424.03M536.71M307.75M173.98M159.24M142.41M
Gross Profit70.39M77.55M48.93M30.18M39.19M34.76M
EBITDA38.91M48.38M19.29M11.29M5.17M12.52M
Net Income24.44M32.10M11.17M2.55M-6.68M19.56M
Balance Sheet
Total Assets505.27M461.60M422.21M377.37M350.58M365.22M
Cash, Cash Equivalents and Short-Term Investments37.25M39.83M32.38M37.61M30.86M31.09M
Total Debt75.56M47.87M69.17M78.17M49.10M42.61M
Total Liabilities179.05M153.76M161.70M125.36M94.83M81.69M
Stockholders Equity293.73M277.11M234.77M228.43M230.85M253.06M
Cash Flow
Free Cash Flow028.04M-2.56M-27.17M-10.38M-28.46M
Operating Cash Flow034.33M11.29M-16.06M5.63M-10.91M
Investing Cash Flow0-2.79M-9.27M-7.14M-15.64M-9.84M
Financing Cash Flow0-24.38M-7.07M30.23M10.38M19.36M

Chia Tai Enterprises International Technical Analysis

Technical Analysis SentimentNegative
Last Price7.70

Price Trends

50DMA7.97Negative
100DMA8.45Negative
200DMA7.94Negative

Market Momentum

MACD-0.14Negative
RSI40.71Neutral
STOCH55.35Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3839, the sentiment is Negative. The current price of 7.70 is above the 20-day moving average (MA) of 7.66, below the 50-day MA of 7.97, and below the 200-day MA of 7.94, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 40.71 is Neutral, neither overbought nor oversold. The STOCH value of 55.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3839.

Chia Tai Enterprises International Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:3839 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:0950HK:095068NeutralHKD 597.67M3.578.02%5.72%7.05%22.46%
HK:3839HK:383961NeutralHKD 1.95B12.017.14%―-22.78%-32.03%
HK:0897HK:089759NeutralHKD 401.18M100.000.34%―-8.30%-44.44%
HK:0570HK:057058NeutralHKD 5.69B-4.65-4.98%0.31%-15.80%-298.94%
HK:0512HK:051254NeutralHKD 15.32B13.386.61%3.94%7.35%-45.49%
HK:3933HK:393354NeutralHKD 14.22B22.053.12%6.57%-12.86%-83.10%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%HK:3839HK:3933HK:0570HK:0897HK:0950HK:0512Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:3839 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:3839Chia Tai Enterprises International 7.701.1116.84%
HK:3933The United Laboratories International7.21-4.41-37.92%
HK:0570China Traditional Chinese Medicine Holdings Co 1.13-1.23-52.12%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.36-0.10-21.74%
HK:0950Lee's Pharmaceutical Holdings Limited1.01-0.68-40.27%
HK:0512Grand Pharmaceutical Group Limited4.29-3.70-46.33%

Chia Tai Enterprises International Corporate Events

CPBIO Reports Unaudited Nine-Month 2026 Results

Nov 11, 2026

CPBIO Holding Company Limited reported unaudited consolidated results for the nine months ended 30 September 2026. Revenue was US$331.617 million, down from US$430.536 million a year earlier, while gross profit fell to US$53.739 million from US$59.59...

CPBIO Shareholders Approve 2026 HOEL Purchase Agreement

Nov 4, 2026

CPBIO Holding Company Limited’s release does not provide information on its industry, products or market focus.Shareholders approved the 2026 Master HOEL Purchase Agreement, related transactions and annual caps at a special general meeting on 4 Novem...

CPBIO Sets November Board Meeting to Approve Nine-Month Unaudited Results

Oct 30, 2026

CPBIO Holding Company Limited has scheduled a board meeting for 11 November 2026 to review and approve the unaudited financial results of the company and its subsidiaries for the nine months ended 30 September 2026. The announcement signals the upcom...

CPBIO Calls Special Meeting to Approve HOEL Supply Agreement Caps

Oct 13, 2026

CPBIO Holding Company Limited has called a special general meeting in Hong Kong on 4 November 2026 for shareholders to vote on approving and ratifying the 2026 Master HOEL Purchase Agreement. The agreement covers the ongoing supply of CPBIO Products...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026